Repositioning Candidate Details
| Candidate ID: | R1524 |
| Source ID: | DB14533 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Zinc chloride |
| Synonyms: | Zinc chloride |
| Molecular Formula: | Cl2Zn |
| SMILES: | [Cl-].[Cl-].[Zn++] |
| Structure: |
|
| DrugBank Description: | Zinc chloride is a solution of ions indicated for use in total parenteral nutrition to maintain zinc levels and prevent deficiency syndromes. Zinc chloride was granted FDA approval before 26 June 1986. |
| CAS Number: | 7646-85-7 |
| Molecular Weight: | 136.315 |
| DrugBank Indication: | Zinc chloride injections are indicated for use total parenteral nutrition to maintain zinc serum levels and prevent deficiency syndromes. |
| DrugBank Pharmacology: | Zinc is a cofactor in many enzymes and mediates a number of catalytic, structural, and regulatory roles in the body. It has a wide therapeutic index and long duration of action, as most zinc in the body is reabsorbed. Patients should be counselled regarding the risk of administration in patients with severe kidney dysfunction. |
| DrugBank MoA: | Zinc performs catalytic, structural, and regulatory roles in the body. Zinc is a component of approximately 3000 human proteins. Zinc is cytoprotective against reactive oxygen species mediated apoptosis through the action of metallothioneins. In a promyelocytic leukemia cell line, zinc enhances the up-regulation of A20 mRNA, which, via the TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of TNF-α, IL-1β, and IL-8 . In patients with diarrhea, zinc restores mucosal barrier integrity, restores enterocyte brush-border enzyme activity, promotes the production of antibodies, and promotes the production of circulating lymphocytes against intestinal pathogens. Zinc also directly affects ion channels as a potassium channel blocker of cAMP-mediated chlorine secretion. Zinc deficiency decreases thymulin, inhibiting T-helper cell maturation and decreased Th-1 cytokines like IL-2. Decreased IL-2 decreases the activity of NK cells and CD8+ T cells. Zinc deficiency also leads to the generation of CD4+ T cells, decreased NF-κB activation, decreased phosphorylation of IκB, and decreased binding of NF-κB to DNA. |
| Targets: | B1 bradykinin receptor agonist; Methylated-DNA--protein-cysteine methyltransferase stabilization; Fructose-bisphosphate aldolase A ligand; Elongation factor 1-alpha 1 binder; Alpha-enolase binder; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific binder; Nucleoside diphosphate kinase A inhibitor; Protein disulfide-isomerase binder; Protein disulfide-isomerase A3 binder; Peroxiredoxin-1 binder; Phosphoserine phosphatase binder; Triosephosphate isomerase binder; Elongation factor Tu, mitochondrial cofactor; Estrogen receptor alpha binder; Interleukin-3 binder; Metallothionein-2 cofactor; Copper chaperone for superoxide dismutase cofactor; Histone deacetylase 1 cofactor; Histone deacetylase 4 cofactor; DNA-3-methyladenine glycosylase cofactor; Semenogelin-1 cofactor; Superoxide dismutase [Cu-Zn] cofactor; Histone deacetylase 8 cofactor; Apoptosis regulatory protein Siva binder; Glycine receptor subunit alpha-1 inhibitor; E3 ubiquitin-protein ligase Mdm2 binder; Insulin stabilization; Utrophin cofactor; Aspartoacylase cofactor; Protein S100-A8 regulator; Protein S100-A9 regulator; Matrix metalloproteinase-9 binder; Tumor protein p73 chaperone; Protein S100-A2 inactivator®ulator; Cellular tumor antigen p53 chaperone; Metallothionein-3 cofactor; Metallothionein-1A binder; Alpha-2-macroglobulin ligand; Alpha-2-HS-glycoprotein chelator; Apolipoprotein A-I inducer&ligand; Apolipoprotein B receptor inducer; Apolipoprotein E antagonist; Apolipoprotein L1 inhibitor; Complement C1q subcomponent subunit B modulator; Complement C1q subcomponent subunit C modulator; Complement C1r subcomponent modulator; Complement C1s subcomponent modulator; Complement C3 inhibitor&ligand; Complement C4-B modulator; C4b-binding protein alpha chain modulator; C4b-binding protein beta chain modulator; Complement C5 ligand; Lys-63-specific deubiquitinase BRCC36 cofactor; Complement factor H ligand; Clusterin inducer; Ceruloplasmin ligand; Carboxypeptidase N catalytic chain cofactor; Carboxypeptidase N subunit 2 cofactor; Dermcidin stabilization; Fibrinogen alpha chain binder; Fibronectin modulator&ligand; Hemoglobin subunit alpha inducer; Hemoglobin subunit beta inducer; Haptoglobin binder; Insulin-like growth factor-binding protein complex acid labile subunit inducer; Inter-alpha-trypsin inhibitor heavy chain H1 binder; Inter-alpha-trypsin inhibitor heavy chain H2 binder; Inter-alpha-trypsin inhibitor heavy chain H3 binder; Inter-alpha-trypsin inhibitor heavy chain H4 binder; Immunoglobulin J chain component of; Plasma kallikrein inhibitor; Kininogen-1 cofactor; Keratin, type I cytoskeletal 9 ligand; Alpha-1-acid glycoprotein 2 binder; N-acetylmuramoyl-L-alanine amidase binder; Serum paraoxonase/arylesterase 1 inducer; Pregnancy zone protein binder; Protein S100-A7 binder; Selenoprotein P binder; Alpha-1-antitrypsin ligand; Alpha-1-antichymotrypsin binder; Corticosteroid-binding globulin modulator; Heparin cofactor 2 agonist; Sex hormone-binding globulin modulator; Serotransferrin ligand; Transthyretin inducer; Vitronectin inducer; Amyloid-like protein 1 ligand; Amyloid-like protein 2 ligand; Amyloid beta A4 protein ligand; Poly [ADP-ribose] polymerase 1 component of; Apolipoprotein B-100 ligand; Hemopexin ligand; Histidine-rich glycoprotein cofactor; Coagulation factor XI activator; C->U-editing enzyme APOBEC-1 cofactor&chelator; Semenogelin-2 cofactor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|